NiKem Research receives certification for GLP Bioanalysis

| Print |
Wednesday, 16 September 2009 11:15 (UTC + 2)

 

NIKEM_logo


Milan, September 16th 2009 / b3c newswire / - NiKem Research is pleased to announce that it has received, from the Italian Ministry of Health, GLP certification of its bioanalysis facilities to further extend its drug discovery service capabilities.

 

NiKem Research has provided for many years high quality cost-effective bioanalytical support both for its in vitro ADME(T) and in vivo PK services associated to various drug discovery programs and as a standalone capability.  We are now able to offer, as a new product, our bioanalysis as a GLP service to support our clients preclinical PK and toxicology studies.  Our new capability allows us to analyse biological samples from all preclinical species, in particular we can:

 

* Provide GLP method development by HPLC or UPLC/MS/MS;
* Resolve clients analytical bottlenecks by providing GLP bioanalytical support for GLP samples sent by the client; 
* Provide, in partnership with EU based companies, specialized in GLP animal dosing, a complete preclinical PK and Toxicokinetic  GLP  service with NiKem providing the GLP bioanalysis and project co-ordination.

 

Giuseppe Giardina, CEO & Managing Director of NiKem, said “This new product is an important step in NiKem’s continuing expansion of its high quality, cost effective services to support progression of our clients’ drug discovery programmes”.



About NiKem Research - www.nikemresearch.com
Based on decades of drug discovery experience, NiKem Research offers a full range of Drug Discovery services to the pharmaceutical industry. In addition to its medicinal chemistry expertise in hit validation and multiparametric lead optimization, NiKem Research offers synthetic chemistry and parallel synthesis capabilities and computational and analytical chemistry services. Furthermore, ADMET profiling, biochemical pharmacology screening and in vivo PK services can be provided either as an integrated Drug Discovery platform, or as individual service modules. NiKem Research usually operates as a fee-for-service partner although other business models can be used to ensure maximum value to our clients. All tangible and intangible assets generated during a collaboration are assigned to the client.



Contact
NiKem Research s.r.l.
Dr. Massimo Dondio
Director of Developability Sciences
Tel. +39 02 35694 7460,
Fax +39 02 35694 7606
This e-mail address is being protected from spambots. You need JavaScript enabled to view it